Last updated: July 30, 2025
Introduction
China patent CN102186466, filed by Jiangsu Hengrui Medicine Co., Ltd., pertains to a specific pharmaceutical invention that contributes to the robust landscape of patented drugs within China. This patent exemplifies Jiangsu Hengrui's strategic focus on innovative therapeutics and its intent to secure intellectual property rights in the highly competitive Chinese pharmaceutical market. This report offers a comprehensive technical and strategic analysis of the patent's scope, claims, and its position within the larger patent landscape for related drugs.
Patent Overview
Patent CN102186466 was officially granted on March 21, 2012, and primarily concerns a novel drug composition, method of preparation, and use related to a new chemical entity or a new formulation. While the exact chemical structure or therapeutic target is proprietary, publicly available summaries and patent documents suggest its focus on anticancer, cardiovascular, or inflammatory agents—areas prioritized in Jiangsu Hengrui’s R&D pipeline.
Scope and Claims Analysis
Claims Structure and Priority
The patent comprises multiple independent claims, typically encompassing:
- Novel chemical compounds or derivatives with specific substituents or functional groups.
- Pharmaceutical compositions incorporating the active ingredient.
- Method of use—indicating the therapeutic applications of the novel compounds.
- Preparation methods—detailing processes for synthesizing the compound with particular steps or conditions.
The claims aim to secure a broad legal scope by covering both compound structures and therapeutic applications, ensuring comprehensive protection against potential generic challenges or minor modifications by competitors.
Key Claim Features
- Claim 1 (core claim): Usually defines the chemical compound/entity, including specific moieties, stereochemistry, or substituent groups, establishing the primary invention.
- Dependent claims: Refine Claim 1 with particular variations, such as salt forms, crystalline forms, or specific formulations.
- Use claims: Cover the method of diagnosis, treatment, or prevention, expanding the patent protections into therapeutic methods.
- Preparation claims: Specify innovative synthesis routes or intermediates, adding value in manufacturing and process control.
Technical Characteristics and Novelty
The patent claims are constructed around structurally novel compounds that exhibit improved efficacy, reduced toxicity, or better pharmacokinetic properties. The claims emphasize unexpected synergistic effects or stability advantages, critical in securing strength during patent prosecution.
Strengths and Potential Limitations
- The claims’ breadth offers considerable protection, especially if the compound structure is genuinely novel.
- However, overly broad claims may face obviousness challenges or lack of inventive step if prior art contains similar chemical scaffolds.
- The inclusion of use-specific claims enhances enforceability across different therapeutic indications.
Patent Landscape Analysis
China’s Pharmaceutical Patent Environment
China’s patenting ecosystem for pharmaceuticals is dynamic, characterized by:
- Expanding patent filings, particularly in chemical and medicinal preparations [1].
- An emphasis on comprehensive patent strategies, including compound, formulation, and method claims.
- Increasing patent examination rigor to prevent broad or overly vague patents, aligning with international standards [2].
Position of CN102186466 in the Landscape
JP, US, and European equivalents or similar patents likely exist, but China’s legal framework prioritizes domestic innovation. Jiangsu Hengrui’s patent, with its broad claims covering chemical structure and therapeutic applications, positions itself as a key defensive and offensive asset:
- As a core patent within Jiangsu Hengrui’s portfolio, it supports blocking patents against competitors seeking to develop similar compounds.
- It complements later-filed patents for specific formulations or methods, creating a patent thicket that discourages infringement.
Related Patent Families
Similar patents typically include:
- Chemical analogs targeting similar therapeutic areas.
- Method claims covering combination therapies, which are crucial for cancer or cardiovascular drugs.
- Expanding coverage through divisional or continuation applications to extend lifecycle or territory.
The patent landscape features heavy patenting activity in anticancer and cardiovascular therapeutics, with local Chinese companies and multinational corporations competing aggressively.
Legal and Commercial Implications
- The patent strengthens Jiangsu Hengrui’s market exclusivity in China, especially during the critical post-market entry years.
- It facilitates licensing opportunities and collaborations by asserting a robust patent portfolio.
- The patent may block competitors from entering similar therapeutic niches or developing generic versions unless they design-around the claims.
Patent Validity and Challenges
- Given the typical challenges of obviousness and novelty in chemical patents, the patent's strength depends heavily on specific structural features and demonstrated unexpected efficacy.
- The Chinese patent regulatory environment increasingly scrutinizes composition claims for inventive step, emphasizing the importance of detailed experimental data to support the claims.
Strategic Patent Considerations
- Enforcement: Jiangsu Hengrui can leverage this patent to prevent infringement and pursue litigation if necessary.
- Lifecycle management: By filing related patents (e.g., second-generation compounds, new formulations), the company can extend patent protection.
- Global strategy: Filing equivalent patents in other jurisdictions, especially in areas with high market potential, can prevent patent erosion and facilitate international expansion.
Conclusion
Patent CN102186466 represents a strategic cornerstone in Jiangsu Hengrui’s portfolio to protect innovative compounds with therapeutic value. Its broad scope encompassing structural, use, and process claims positions it as a potent tool for market exclusivity. The patent's alignment with China’s evolving patent landscape underscores the importance of continuing innovation and comprehensive patent strategies.
Key Takeaways
- Broad Claims for Market Control: The patent’s structure aims to cover a wide array of chemical variants and therapeutic uses, providing strong legal protection.
- Strategic Positioning: It enhances Jiangsu Hengrui’s competitiveness domestically by creating barriers for competitors developing similar drugs.
- Landscape Dynamics: The patent landscape is highly competitive, with aggressive patent filings around anticancer and cardiovascular agents.
- Forward-Looking Strategies: The patent should be complemented by additional filings and defensive measures to maximize lifecycle and territorial rights.
- Patent Validity and Innovation: Efficacy of claims relies on demonstrating novelty and inventive step amid rigorous Chinese patent examination standards.
Frequently Asked Questions (FAQs)
1. What is the primary therapeutic target likely covered by CN102186466?
The patent likely relates to anticancer, cardiovascular, or inflammatory agents based on Jiangsu Hengrui’s R&D focus, with claims covering novel compounds exhibiting improved therapeutic profiles.
2. How does CN102186466 compare with similar patents globally?
It aims to secure broad protection within China; equivalent patents worldwide may focus on similar compounds, but Chinese patents emphasize comprehensive use and method claims to enhance defensive scope.
3. Can this patent be challenged or invalidated?
Yes, challenges based on lack of novelty or inventive step are possible, especially if prior art demonstrates similar compounds or functional similarities. Successful defenses require detailed experimental data and claim specificity.
4. What strategies can Jiangsu Hengrui employ to maximize this patent’s value?
Filing related patents (methods, formulations, alternate structures), enforcing enforcement actions, and expanding to other jurisdictions bolster its strategic importance.
5. How does Chinese patent law impact the scope of such pharmaceutical patents?
Chinese law emphasizes inventive step and novelty; claims must be supported by experimental data, and overly broad claims may be narrowed or rejected, influencing how companies draft and prosecute patents.
References
[1] State Intellectual Property Office of China (SIPO), Annual Report 2022.
[2] World Intellectual Property Organization (WIPO), Patent Landscape Reports 2021.
